title: [Rifaksimin in complex treatment of Helicobacter pylori infection in children (a pilot study)].
abstract: OBJECTIVE
  To provide a pilot study of empiric rifaximin, bismuth subcitrate, furazolidone/nifuratel triple therapy for H. pylori gastritis in childhood.
  
  
  METHODS
  Forty one pediatric outpatients (27 females, mean age 14.5+/-1.4 ys) with H. pylori-associated chronic gastritis who underwent endoscopy for dyspeptic symptoms received the combination of bismuth subcitrate (8 mg/kg/day, q. d. s.) for 14 days, rifaximin (800 mg/day) for 10 days and furazolidone (10 mg/kg/day, q. d. s.) or nifuratel (15 mg/kg/two times daily) for 10 days. H. pylori status was determined before the treatment by modified Giemsa staining/urease test and after the treatment (in 4-6 weeks) by ammonia breath test.
  
  
  RESULTS
  H. pylori was eradicated in 35 children (85.4%; 95%CI: 75.4-96.4 ITT and PP tests). There were no serious adverse reactions and were no withdrawals due to any side effects.
  
  
  CONCLUSIONS
  The combination of rifaximin, bismuth subcitrate and furazolidone/nifuratel was an effective and tolerable regimen for initial H. pylori eradication.
authors.forename: A A
authors.initials: AA
authors.lastname: Nizhevich
authors.forename: P L
authors.initials: PL
authors.lastname: Shcherbakov
authors.forename: E N
authors.initials: EN
authors.lastname: Akhmadeeva
mesh_terms: D000293:Adolescent; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001944:Breath Tests; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D005664:Furazolidone / Q000008:administration & dosage / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008297:Male; D009545:Nifuratel / Q000008:administration & dosage / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D010865:Pilot Projects; D012294:Rifamycins / Q000008:administration & dosage / Q000627:therapeutic use*; D000078262:Rifaximin; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D009942:Organometallic Compounds; D012294:Rifamycins; D005664:Furazolidone; C002791:bismuth tripotassium dicitrate; D000078262:Rifaximin; D009545:Nifuratel